Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α‐Positive Advanced Ovarian Cancer
Yongsheng Li, Li Yuan, Ge Lou, Hongbing Cai, Yuzhi Li, Fenghu Li, Li Wang, Xingtao Long, Yi Gong, Chaonan Zhu, Li Li, June Xu, Qi Zhou · 2026
Read Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α‐Positive Advanced Ovarian Cancer by Yongsheng Li, Li Yuan, Ge Lou, Hongbing Cai, Yuzhi Li, Fenghu Li, Li Wang, Xingtao Long, Yi Gong, Chaonan Zhu, Li Li, June Xu, Qi Zhou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13239540.txt.
Description
Yongsheng Li and co-authors report a first trial in China of a targeted ovarian cancer drug, in this 2026 paper. The drug aims at a surface protein found on many ovarian tumors and carries a cell-killing payload. Patients in the trial had cancers that no longer answered standard platinum drugs.
Nineteen patients joined the dose-rising and dose-expansion stages. Most side effects were manageable; the most common severe ones were drops in blood cell counts. Blood tests tracked how the drug moved through the body. The paper gives early safety and dosing data to guide larger trials of the drug in Chinese patients.
Catalog record
| CREATOR | Yongsheng Li, Li Yuan, Ge Lou, Hongbing Cai, Yuzhi Li, Fenghu Li, Li Wang, Xingtao Long, Yi Gong, Chaonan Zhu, Li Li, June Xu, Qi Zhou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |